EverlyWell, an Austin, Texas-based digital health company, raised $50m in financing.
The round was led by Goodwater Capital with Highland Capital Partners joining. Next Coast Ventures, NextGen Venture Partners, SoGal Ventures and others participated.
The company will use the funding to expand its digital platform and scale existing partnerships with leading brands like CVS and Humana.
Led by founder and CEO Julia Cheek, Chief Technology Officer Nick Parker, CMO Jenifer Dasho and Executive Medical Director Dr. Marra Francis, EverlyWell offers 35 validated lab tests that start at $49 and include Food Sensitivity, Fertility, Cholesterol, STDs, Thyroid and more. Its digital platform connects consumers with existing, independent, certified labs for at-home collection tests that are ordered and reviewed by board-certified physicians. Once the sample is submitted, online results with evidence-based insights, suggestions and next steps are provided to consumers within days.
In addition, the company has launched an end-to-end care model for consumers, now offering an independent physician consult and prescription, if appropriate, for select STDs and Lyme Disease testing. All of this is included in an upfront price before purchase.
As part of the announcement, EverlyWell has appointed Dr. Robert Langer as the head of its Scientific Advisory Board.